@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RArTqwSNEOYt6RMAbI0hgbvR96IOkhucTyM8UOndt8trU> .
@prefix sub: <http://purl.org/np/RArTqwSNEOYt6RMAbI0hgbvR96IOkhucTyM8UOndt8trU#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:association rdf:object <https://identifiers.org/MONDO:0005086>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/PUBCHEM.COMPOUND:25102847>;
    a rdf:Statement;
    rdfs:label "cabometyx is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma rcc 1 1 patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib 1 2 cabometyx is indicated for the treatment of patients with advanced renal cell carcinoma rcc cabometyx is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/MONDO:0005086> bl:category bl:Disease .
  
  <https://identifiers.org/PUBCHEM.COMPOUND:25102847> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "WZesJOKUsQfIVw05I0EdjZJ5h85G+OZbRucsd/LMsaBl0o3cVq6/1OfQ3t+StMHcvxB8gz/eEFQqQx8hLZYQtTiyLqFWmD1h8X1DOCszmCa+7lupstgSOTtb3IEzDNgjCLZVUc/K+JvTK6jg4bfezGSWd+tIHpvOwqZQbTu3tXg=";
    npx:hasSignatureTarget this: .
  
  this: dc1:created "2021-06-08T21:12:37.194+02:00"^^xsd:dateTime;
    dc1:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}